Mandel VD, et al. - Authors evaluated the effectiveness, safety, and recurrence of symptoms in a real-life experience of omalizumab as an add-on therapy for H₁-antihistamine-refractory chronic spontaneous urticaria (CSU) patients (refractory CSU). They selected the patients that were previously treated with second-generation antihistamines at a fourfold increased dose without clinical responses at 4 weeks of treatment. As per data, for refractory CSU, add-on omalizumab therapy in a real-life setting seemed to be effective and safe with a relatively low incidence of symptom recurrence.